Search

Displaying results 1201 - 1210 of 7479 in total
  1. Drug

    Oxogluric acid

    go.drugbank.com/drugs/DB08845
    InvestigationalNutraceutical

    Oxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. … In the United States a phase I clinical trial is investigating whether oxogluric acid precursors found in nutritional supplements can benefit patients with the metabolic disorder propionic acidemia.

  2. Drug

    Felbamate

    go.drugbank.com/drugs/DB00949
    Approved

    Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).

  3. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

    Products: Van-letrozole
  4. Drug

    Sevoflurane

    go.drugbank.com/drugs/DB01236
    ApprovedInvestigationalVet approved

    Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. … [A249910] Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.[A249885]

  5. Drug

    Bismuth subnitrate

    go.drugbank.com/drugs/DB13209
    ApprovedWithdrawn

    The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.

  6. Drug

    Nefazodone

    go.drugbank.com/drugs/DB01149
    ApprovedWithdrawn

    Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. … Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.

  7. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [A229103] Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is not a first line treatment due to significant adverse effects.

    Products: Nu-trihexyphenidyl
  8. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) … This small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation.

  9. Drug

    Eniluracil

    go.drugbank.com/drugs/DB03516
    Investigational

    Eniluracil could improve 5-FU by increasing its effectiveness, reducing its side effects and/or making it orally available. … Eniluracil has received Orphan Drug status from the FDA for the treatment of hepatocellular cancer in combination with fluoropyrimidines (including 5-FU).

  10. Drug

    Shark liver oil

    go.drugbank.com/drugs/DB11088
    Approved

    Shark oil is extracted from the livers of sharks, which can account for up to 25% of their total body weight. … The potential benefit of shark oil has been experimented in different therapeutic implications, where it is claimed to improve immune responses and exert an antitumor activity.

    Mixtures: DG Health Hemorrhoidal